Project Grant K99HL177608
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$112K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...
The National Heart Lung and Blood Institute (NHLBI) awarded a $164,700 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to study the role of mTOR hyperactivation in pulmonary vascular remodeling. The research aims to examine how mTOR activation in specific mesenchymal cell populations alters endothelial cell behavior and function, and how aberrant mTOR...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $723,084 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to The Regents of the University of Colorado, doing business as the University of Colorado-Denver. The objective of this 4-year grant is to determine the contribution of the PAR1/IL-17 signaling axis to the development of abnormal cellular phenotypes in chronic thrombus, and the initiation and progression of chronic thromboembolic pulmonary hypertension...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $657,308 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the CXCL12 signaling axis and its role in pulmonary arterial heterogeneity, development, and disease. The key objectives of this 12-month project are to: 1) define the spatiotemporal role of CXCL12 signaling in pulmonary vascular development, 2)...
This federal Project Grant award of $1,127,798 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to understand the role of macrophages in preserving cardiovascular health and their contributions to cardiovascular disease (CVD). The overarching goal is to identify new therapeutic targets for CVD in both female and male patients. The research will use advanced single cell imaging and omics techniques to characterize harmful...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the role of sickle red blood cells (RBCs) in activating neutrophils and promoting vaso-occlusion in sickle cell disease (SCD). The key objectives of the research are to: 1) delineate the characteristics of sickle RBCs that contribute to neutrophil activation, 2) examine the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,659,996 to the University of Southern California (USC) from April 1, 2025 to January 31, 2029. The funding supports research to investigate the role of the protein PDLIM2 in regulating alveolar macrophage function, which is critical for lung innate immunity, inflammation, and respiratory diseases. The research aims to elucidate the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,940 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) with a project period from Sep 20, 2024 to Aug 31, 2029. The grant aims to develop a novel mouse model of flow-induced pulmonary hypertension (PH) that better represents the physiological conditions observed in patients with congenital heart disease. Additionally, the project...
This Project Grant award of $498,000 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research by National Jewish Health to investigate the role of RNA editing in pulmonary hypertension. The research aims to determine how the enzyme ADAR1-mediated RNA editing regulates the expression and function of the gene NOCT in pulmonary artery endothelial cells, and the impact on pulmonary hypertension development. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $522,794 to the University of Illinois to conduct research on the role of the voltage-gated proton channel HV1 in the development of pulmonary hypertension. The project aims to use transgenic mice and in vivo approaches to delineate HV1's contributions to pulmonary hypertension pathogenesis, examine the molecular mechanisms, and...